The development of de novo renal cell carcinoma (RCC) in a transplanted kidney is a rare condition. Currently, this is the second case report of a 41-year-old man in whom carcinoma of a renal allograft was detected by contrast-enhanced ultrasound (CEUS). An abdominal CT scan was not conclusive enough to differentiate between septal enhancement of a cyst and a low vascularized tumor. CEUS confirmed a solid, homogeneously enhancing but hypoechoic and hypovascular lesion compared to the surrounding kidney parenchyma without septal enhancement. Therefore, the patient underwent nephron-sparing surgery (NSS), affirming papillary RCC type 2. Graft function remained unchanged postoperatively; 12 months after NSS, no local recurrence or distant metastasis was described. CEUS seems to be a minimally invasive and efficient imaging option if other diagnostic tools cannot clearly exclude RCC, with the advantage of wide-ranging use, especially in cases of impaired renal function.

Keywords:
Contrast-enhanced ultrasound, Kidney transplantation, Nephron-sparing surgery, Partial nephrectomy, Renal cell carcinoma, Renal allograft, Sonography, Ultrasound
1.
Lentini P, Granata A, Ciancio A, Gallieni M: Regular ultrasound examination of transplanted kidneys allows early diagnosis of renal cell carcinoma and conservative nephron sparing surgery. Arch Ital Urol Androl 2011;83:195-199.
2.
Végső G, Toronyi É, Deák PÁ, Doros A, Langer RM: Detection and management of renal cell carcinoma in the renal allograft. Int Urol Nephrol 2013;45:93-98.
3.
Olivani A, Iaria M, Missale G, et al: Percutaneous ultrasound-guided radiofrequency ablation of an allograft renal cell carcinoma: a case report. Transplant Proc 2011;43:3997-3999.
4.
Hoda MR, Hamza A, Wagner S, Greco F, Fornara P: Recurrence of renal cell carcinoma in a renal allograft after partial transplant nephrectomy: a case report. Urol Int 2009;83:239-241.
5.
Barama A, St-Louis G, Nicolet V, Hadjeres R, Daloze P: Renal cell carcinoma in kidney allografts: a case series from a single center. Am J Transplant 2005;5:3015-3018.
6.
Krishnamurthi V, Novick AC: Nephron-sparing surgery in a renal allograft. Urology 1997;50:132-134.
7.
Grzelak P, Szymczyk K, Strzelczyk J, et al: Perfusion of kidney graft pyramids and cortex in contrast-enhanced ultrasonography in the determination of the cause of delayed graft function. Ann Transplant 2011;16:48-53.
8.
Ignee A, Hocke M, Selbach J, Cui XW, Woenckhaus M, Dietrich CF: Papillary renal cell carcinoma in the transplanted kidney - a case report focusing on contrast enhanced ultrasound features. Med Ultrason 2012;14:246-250.
9.
Zavos G, Kakisis J, Bokos J, Pappas P, Boletis J, Kostakis A: De novo renal cell carcinoma in a kidney allograft 13 years after transplantation: a case report and review of the literature. Urol Int 2007;78:283-285.
10.
Wunderlich H, Wilhelm S, Reichelt O, Zermann DH, Börner R, Schubert J: Renal cell carcinoma in renal graft recipients and donors: incidence and consequence. Urol Int 2001;67:24-27.
11.
Swords DC, Al-Geizawi SM, Farney AC, et al: Treatment options for renal cell carcinoma in renal allografts: a case series from a single institution. Clin Transplant 2013;27:E199-E205.
12.
McHayleh W, Morcos JP, Wu T, et al: Renal cell carcinoma from a transplanted allograft: two case reports and a review of the literature. Clin Genitourin Cancer 2008;6:53-55.
13.
Tay KJ, Ho HS, Low AS, Cheng CW: Is contrast enhanced ultrasound a valid alternative diagnostic modality for renal cell carcinoma in patients with renal impairment? Ann Acad Med Singapore 2012;41:127-128.
14.
Braunagel M, Graser A, Reiser M, Notohamiprodjo M: The role of functional imaging in the era of targeted therapy of renal cell carcinoma. World J Urol 2014;32:47-58.
15.
Hora M, Hes O, Reischig T, et al: Tumours in end-stage kidney. Transplant Proc 2008;40:3354-3358.
16.
Vikram R, Ng CS, Tamboli P, et al: Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics 2009;29:741-754; discussion 755-757.
17.
Clevert DA, Bensler S, Stickel M, et al: Contrast-enhanced ultrasound eases interpretation of an unclear renal tumor in addition to CT, MRI and histological findings - a case report in a young patient. Clin Hemorheol Microcirc 2007;36:313-318.
18.
Miyamoto K, Inoue S, Kajiwara M, Teishima J, Matsubara A: Comparison of renal function after partial nephrectomy and radical nephrectomy for renal cell carcinoma. Urol Int 2012;89:227-232.
19.
Yasuda Y, Yuasa T, Yamamoto S, Urakami S, Ito M, Sukegawa G, Kitsukawa S, Yonese J, Fukui I: Evaluation of the RENAL nephrometry scoring system in adopting nephron-sparing surgery for cT1 renal cancer. Urol Int 2013;90:179-183.
20.
Wszolek MF, Kenney PA, Lee Y, Libertino JA: Comparison of hilar clamping and non-hilar clamping partial nephrectomy for tumours involving a solitary kidney. BJU Int 2011;107:1886-1892.
21.
Goeman L, Joniau S, Oyen R, Van Poppel H: Percutaneous ultrasound-guided radiofrequency ablation of recurrent renal cell carcinoma in renal allograft after partial nephrectomy. Urology 2006;67:199.
22.
Ljungberg B, Cowan NC, Hanbury DC, et al; European Association of Urology Guideline Group: EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398-406.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.